

Matthew L Meizlish

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4457648/publications.pdf>

Version: 2024-02-01

11
papers

1,888
citations

1040056

9
h-index

1372567

10
g-index

17
all docs

17
docs citations

17
times ranked

4435
citing authors

#	ARTICLE	IF	CITATIONS
1	Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. <i>Lancet Haematology</i> , 2020, 7, e575-e582.	4.6	848
2	A neutrophil activation signature predicts critical illness and mortality in COVID-19. <i>Blood Advances</i> , 2021, 5, 1164-1177.	5.2	241
3	Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, .	11.9	153
4	Tissue Homeostasis and Inflammation. <i>Annual Review of Immunology</i> , 2021, 39, 557-581.	21.8	143
5	Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. <i>American Journal of Hematology</i> , 2021, 96, 471-479.	4.1	129
6	Circulating markers of angiogenesis and endotheliopathy in COVID-19. <i>Pulmonary Circulation</i> , 2020, 10, 1-4.	1.7	103
7	Principles of Cell Circuits for Tissue Repair and Fibrosis. <i>Science</i> , 2020, 23, 100841.	4.1	90
8	The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. <i>Neuro-Oncology</i> , 2013, 15, 1479-1490.	1.2	72
9	No Time for Silence: An Urgent Need for Political Activism Among the Medical Community. <i>Academic Medicine</i> , 2017, 92, 1231-1233.	1.6	14
10	Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis. <i>Blood</i> , 2020, 136, 23-24.	1.4	3
11	In Reply to Fisher. <i>Academic Medicine</i> , 2018, 93, 153.	1.6	0